Shoulder Pain and PNS
Shoulder pain is a prevalent musculoskeletal complaint that affects approximately 18–26% of adults and accounts for over 12 million outpatient visits annually (Arulkumar et al., 2024). Although many acute cases resolve within several weeks, nearly 40% progress to chronic, persistent pain lasting longer than three months, leading to substantial functional impairment and decreased quality of life (Mazzola & Spinner, 2020). The shoulder’s wide range of motion and biomechanical complexity make it highly vulnerable to both degenerative and neuropathic processes.
Mechanistically, shoulder pain arises from nociceptive, neuropathic, or mixed pathways. Nociceptive pain often reflects tissue injury or degeneration involving the rotator cuff, subacromial bursa, glenohumeral cartilage, or periarticular soft tissues (Mazzola & Spinner, 2020). Neuropathic pain develops when the suprascapular or axillary nerves—the primary sensory and motor innervators of the shoulder—undergo compression, traction, or irritation, generating radiating pain, weakness, or burning sensations (Arulkumar et al., 2024). Chronic cases may exhibit central sensitization, wherein spinal and supraspinal processing amplifies pain independent of peripheral pathology.
Clinically, shoulder pain encompasses a broad spectrum of etiologies, including rotator cuff tendinopathy and tears, glenohumeral osteoarthritis, adhesive capsulitis, impingement syndrome, labral injuries, postoperative pain, and hemiplegic shoulder pain following stroke (Mazzola & Spinner, 2020). Severe or refractory presentations—particularly osteoarthritis, poststroke pain, and post-arthroplasty syndromes—often fail conservative therapies such as physical therapy, NSAIDs, corticosteroid injections, and nerve blocks. These cases contribute disproportionately to disability, sleep disruption, and loss of upper-extremity function (Arulkumar et al., 2024).
Given this heterogeneous clinical and mechanistic landscape, modern management increasingly emphasizes individualized treatment strategies, with peripheral nerve stimulation emerging as a viable option for chronic, treatment-resistant shoulder pain.
Why Periphereal Nerve Stimulation for Shoulder Pain
Understanding Shoulder Pain: A Comprehensive Overview
Peripheral nerve stimulation (PNS) has emerged as a targeted, minimally invasive therapy for chronic shoulder pain, particularly for patients who fail conservative treatments such as physical therapy, NSAIDs, injections, or radiofrequency ablation. The rationale for PNS in shoulder pain is grounded in the shoulder’s neuroanatomy: the suprascapular and axillary nerves provide the majority of sensory input to the glenohumeral and acromioclavicular joints, as well as motor innervation to the rotator cuff and deltoid musculature (Mazzola & Spinner, 2020). Because these nerves are major conduits of both nociceptive and neuropathic signals, modulating their activity offers a direct mechanism for analgesia.
Mechanistically, PNS delivers controlled electrical stimulation through percutaneously placed microleads, altering peripheral nerve excitability and engaging dorsal horn inhibitory pathways. This produces segmental analgesia through large-fiber activation consistent with gate-control theory, but also triggers broader central effects involving descending inhibitory pathways, autonomic modulation, and neuroimmune interactions (Arulkumar et al., 2024; Kaye et al., 2021). These multi-level actions make PNS particularly suitable for persistent shoulder pain, where both peripheral pathology and central sensitization frequently coexist.
Clinically, PNS addresses several gaps in current shoulder pain management. Many structural shoulder disorders—such as severe rotator cuff degeneration, glenohumeral osteoarthritis, or poststroke hemiplegic shoulder pain—respond incompletely to standard therapies and may not be amenable to surgery. PNS provides a non-destructive alternative that can reduce pain, restore mobility, and minimize reliance on opioids (Abarca et al., 2024). Moreover, the ability to target either the suprascapular nerve, the axillary nerve, or both enables a tailored approach depending on the patient’s pain distribution and pathology (Shah et al., 2023).
A growing body of real-world evidence and clinical studies demonstrates meaningful reductions in pain intensity, improvements in shoulder function, and enhanced quality of life following PNS, with benefits often extending beyond the stimulation period (Gutierrez et al., 2024). These findings, combined with a favorable safety profile and the outpatient nature of the procedure, underscore why PNS is increasingly considered a viable and promising option for chronic, treatment-resistant shoulder pain.
Periphereal Nerve Stimulation Procedure & Targets in Shoulder Pain
Peripheral nerve stimulation (PNS) for shoulder pain is a minimally invasive neuromodulation procedure designed to modulate afferent signaling from the suprascapular and axillary nerves—the two dominant sensory pathways supplying the glenohumeral and acromioclavicular joints. The modern PNS procedure utilizes percutaneously inserted, small-caliber leads placed under ultrasound or fluoroscopic guidance to achieve precise anatomic targeting while minimizing procedural risk (Mazzola & Spinner, 2020). Technological advancements in thin microleads and external pulse generators have significantly improved safety, procedural ease, and long-term applicability.
Procedural Workflow
PNS can be performed as a temporary 60-day system or as a permanent implant depending on the clinical scenario and payer requirements. Most procedures begin with a diagnostic nerve block or stimulation trial to confirm the appropriateness of the target nerve (Abarca et al., 2024). With the patient in a prone or lateral position, ultrasound is used to visualize the shoulder’s neural and bony structures, allowing the operator to avoid vascular structures and confirm stable lead placement. Real-time stimulation testing ensures concordance between paresthesia distribution and the patient’s painful region (Shah et al., 2023).
Primary Targets
Suprascapular Nerve
The suprascapular nerve contributes nearly 70% of sensory input to the shoulder joint and provides motor innervation to the supraspinatus and infraspinatus. It is typically accessed at the suprascapular notch or spinoglenoid notch, where the nerve lies beneath the transverse ligament. Ultrasound guidance offers clear visualization of the nerve and adjacent suprascapular artery, enabling safe placement of the lead just inferior to the ligament (Mazzola & Spinner, 2020). This target is particularly effective for rotator cuff pathology, glenohumeral osteoarthritis, adhesive capsulitis, and poststroke shoulder pain.
Axillary Nerve
The axillary nerve is targeted posterolaterally at the inferior border of the teres minor muscle as it courses around the humerus within the quadrilateral space. This approach provides broad coverage for lateral shoulder and deltoid pain and is particularly useful after shoulder surgery or in patients with rotator cuff insufficiency (Arulkumar et al., 2024). Doppler ultrasound can help distinguish the nerve from the posterior circumflex humeral artery, ensuring accurate placement (Shah et al., 2023).
Dual-Target & Advanced Strategies
For patients with diffuse or refractory pain, dual suprascapular-axillary PNS can provide more comprehensive analgesia and functional improvement. Real-world datasets report that selecting the correct combination of targets enhances outcomes and reduces the risk of lead migration or suboptimal coverage (Gutierrez et al., 2024).
Together, these procedural and anatomical advantages make PNS a precise, adaptable, and evidence-supported intervention for chronic shoulder pain unresponsive to conventional therapies.
Clinical Outcomes & Long-Term Efficacy of PNS in Shoulder pain
Peripheral nerve stimulation (PNS) has shown increasing evidence of effectiveness for chronic shoulder pain across diverse etiologies, including rotator cuff pathology, glenohumeral osteoarthritis, adhesive capsulitis, postoperative pain, and hemiplegic shoulder pain following stroke. The majority of published clinical experience focuses on stimulation of the suprascapular and axillary nerves, which are the dominant sensory pathways of the shoulder (Mazzola & Spinner, 2020). Both short-term (60-day) systems and permanent implants have demonstrated meaningful and durable pain reduction in carefully selected patients.
Early observational studies reported substantial improvements in pain intensity, range of motion, and function when targeting either nerve individually or in combination. Suprascapular nerve PNS has been associated with improvements in pain scores, abduction strength, and sleep quality in patients with refractory degenerative and neuropathic shoulder pain. Meanwhile, axillary nerve PNS has been particularly beneficial for patients with deltoid-dominant or lateral shoulder pain distributions, frequently yielding dramatic improvements when suprascapular lead placement alone provided only partial relief (Shah et al., 2023).
Real-world data further support these findings. In a retrospective cohort evaluating temporary 60-day PNS for shoulder pain, a significant proportion of patients achieved ≥50% pain reduction that persisted for months beyond lead removal, suggesting prolonged neuromodulatory effects (Gutierrez et al., 2024). Similar reports in elderly patients with chronic rotator cuff pathology demonstrate sustained functional recovery and reduced need for analgesics up to two years after treatment, even among individuals considered poor surgical candidates (Abarca et al., 2024).
Long-term outcomes appear most robust in poststroke hemiplegic shoulder pain, where randomized and controlled studies have demonstrated clinically meaningful reductions in pain intensity, improved tone, and enhanced upper-extremity mobility. These benefits likely reflect modulation of both peripheral nociception and central sensitization pathways, which are prominent contributors to poststroke pain syndromes (Arulkumar et al., 2024).
Overall durability varies based on pathology, nerve target, and stimulation duration, but many patients maintain relief for 6–12 months or longer. Permanent systems may offer more consistent long-term benefits, whereas temporary systems can still produce prolonged improvements through neuroplastic mechanisms (Kaye et al., 2021). Across the literature, reductions in opioid consumption, improvements in daily function, and meaningful enhancements in quality of life are recurrent findings.
Collectively, current evidence supports PNS as a clinically effective and often durable treatment option for chronic shoulder pain, especially when conventional therapies have failed and surgical interventions are not feasible or desired.
Side Effects & Safety Profile
Peripheral nerve stimulation (PNS) for shoulder pain is generally considered a safe, low-risk intervention with a favorable safety profile compared to more invasive surgical or ablative procedures. Advances in micro lead design, percutaneous implantation techniques, and real-time ultrasound guidance have significantly reduced the incidence of serious complications (Mazzola & Spinner, 2020). Most adverse events reported in the literature are mild, self-limited, and related to the superficial nature of the procedure.
The most common side effects include local site discomfort, minor bleeding, bruising, or transient paresthesia immediately after lead placement. Skin irritation or mild inflammation at the exit site can also occur, particularly with externalized temporary systems (Abarca et al., 2024). Lead migration is possible but has become far less frequent with improved anchoring designs and optimized placement techniques (Arulkumar et al., 2024). Infection risk remains low, especially when strict sterile technique is followed; large safety cohorts have reported no serious or unexpected device-related adverse events (Kaye et al., 2021).
Rare complications include allergic reactions to components of the implanted system or stimulation-induced muscle twitching if the lead is positioned too close to a motor branch. These issues are typically manageable through reprogramming or minor lead adjustment. Importantly, unlike radiofrequency ablation or surgical interventions, PNS is non-destructive and fully reversible, making it a safer option for patients with complex or refractory shoulder pain.
Overall, existing data consistently demonstrate that PNS is a well-tolerated therapy with a strong safety profile, supporting its use as a minimally invasive alternative for patients who have not benefited from conventional treatments.
What to Expect During Recovery and Follow-Up
Recovery after peripheral nerve stimulation (PNS) for shoulder pain is typically smooth and minimally disruptive, reflecting the percutaneous and non-destructive nature of the procedure. Most patients can resume light daily activities within 24 hours, with only mild soreness or bruising at the insertion site, which generally resolves quickly (Mazzola & Spinner, 2020). Because the leads are placed under real-time ultrasound guidance, tissue trauma is minimal, reducing early postoperative discomfort and accelerating return to function.
During the initial few days, patients may notice tingling sensations or intermittent paresthesias as stimulation settings are adjusted. These sensations are expected and often indicate that the lead is effectively engaging the target nerve (Arulkumar et al., 2024). Clinicians typically perform an initial programming session on the day of the procedure, followed by fine-tuning in subsequent visits to ensure optimal coverage of the patient’s pain distribution (Shah et al., 2023).
For temporary 60-day systems, patients are instructed on managing the external components and keeping the site clean and dry. Follow-up visits focus on monitoring lead stability, adjusting stimulation parameters, and assessing early clinical response (Gutierrez et al., 2024). Most individuals begin to experience meaningful pain reduction within 1–3 weeks, although some may require longer as central and peripheral modulation processes evolve.
Patients with permanent implants undergo a similar but slightly more structured follow-up schedule, including periodic device checks, battery assessments, and long-term programming adjustments. Encouragingly, many patients report sustained pain relief, functional gains, and improved sleep even after temporary systems are removed, suggesting that neuromodulatory effects persist beyond active stimulation (Abarca et al., 2024).
Activity restrictions after PNS are minimal. Patients are typically advised to avoid heavy lifting or abrupt shoulder movements for the first week to reduce the risk of lead migration. Physical therapy may be initiated once pain is controlled, especially for those with rotator cuff deficits, adhesive capsulitis, or poststroke functional limitations.
Overall, recovery and follow-up after shoulder PNS are characterized by rapid return to daily routines, structured but low-burden monitoring, and progressive improvement in pain and function, making it a patient-friendly treatment pathway for chronic shoulder pain.
Predictors of Successful PNS Outcomes
Successful outcomes with peripheral nerve stimulation (PNS) for shoulder pain depend on a combination of patient characteristics, pain mechanisms, and procedural accuracy. One of the most consistent predictors is the correct identification of the primary pain source, as PNS has the greatest effect when the suprascapular or axillary nerve corresponds anatomically and symptomatically to the patient’s pain pattern (Mazzola and Spinner, 2020). Patients whose pain includes neuropathic or mixed features, such as those with rotator cuff degeneration, glenohumeral osteoarthritis, or poststroke hemiplegic shoulder pain, typically demonstrate better therapeutic responses.
A strong response to diagnostic nerve blocks is another reliable predictor of success. Temporary pain reduction after suprascapular or axillary nerve block indicates that the targeted nerve is contributing significantly to the pain experience and therefore is a suitable candidate for neuromodulation (Abarca et al., 2024). Suprascapular block response is often associated with intraarticular or superior shoulder pathology, whereas axillary block response tends to predict benefit in patients who localize their pain laterally or within the deltoid region (Shah et al., 2023).
Technical factors also play a substantial role. Optimal lead placement parallel to the nerve, combined with real time ultrasound guidance, increases accuracy and reduces the risk of suboptimal stimulation or lead-related complications. Proper intraoperative testing to confirm appropriate sensory coverage further enhances long term outcomes (Arulkumar et al., 2024).
Patient level variables contribute meaningfully as well. Shorter duration of symptoms, preserved range of motion, and lower degrees of structural deformity generally correlate with improved results. Patients with central sensitization related to stroke may also respond particularly well due to PNS’s dual peripheral and central mechanisms (Kaye et al., 2021). Conversely, uncontrolled psychological distress, opioid overuse, or limited engagement in rehabilitation can negatively affect outcomes.
Consistent follow up after implantation remains important. Adjusting stimulation parameters, adhering to activity recommendations, and participating in physical therapy contribute to sustained improvements in pain and function (Gutierrez et al., 2024).
Summary
Peripheral nerve stimulation (PNS) has increasingly established itself as a rational and effective therapeutic approach for chronic shoulder pain, a condition that often resists conventional interventions due to the joint’s complex anatomy and multifactorial pain mechanisms. The suprascapular and axillary nerves account for the majority of sensory input to the glenohumeral and acromioclavicular joints, and because shoulder pain frequently involves neuropathic or mixed nociceptive–neuropathic processes, modulating these nerves provides a direct strategy for reducing persistent pain (Mazzola and Spinner, 2020). The procedure’s minimally invasive nature and the ability to perform it under real-time ultrasound guidance further position PNS as an accessible option for a wide range of patients.
Mechanistic studies highlight that PNS influences both peripheral and central pathways. By delivering controlled electrical impulses to targeted nerves, PNS reduces ectopic firing, enhances segmental inhibition, and modulates ascending and descending central pathways involved in chronic pain processing (Kaye et al., 2021). These mechanisms explain the sustained improvements seen even after temporary systems are removed, suggesting durable neuroplastic changes rather than transient analgesic effects. Because central sensitization contributes significantly to chronic shoulder pain—especially in poststroke populations—PNS’s multi-level neuromodulatory impact is clinically relevant (Arulkumar et al., 2024).
Clinical evidence across multiple studies supports the effectiveness of PNS in reducing pain intensity, improving functional mobility, restoring sleep patterns, and decreasing opioid reliance. Suprascapular nerve stimulation consistently benefits patients with rotator cuff disease, glenohumeral osteoarthritis, and adhesive capsulitis, while axillary nerve stimulation is particularly effective for lateral shoulder pain and deltoid-dominant symptoms (Shah et al., 2023). In real-world cohorts, temporary 60-day systems demonstrate high responder rates, with many patients maintaining significant relief well beyond explantation, highlighting both peripheral and central adaptations (Gutierrez et al., 2024). Older adults and nonsurgical candidates show especially high success rates, underscoring PNS’s role as a vital option for populations with limited therapeutic alternatives (Abarca et al., 2024).
Safety data consistently reveal that PNS is well tolerated. Reported complications are minimal and typically limited to temporary soreness, skin irritation, or minor lead issues, all of which are manageable without long-term consequences. The absence of nerve destruction or permanent anatomical alteration is an important advantage compared to ablative interventions (Mazzola and Spinner, 2020).
Predictors of successful outcomes include accurate pain-source identification, positive diagnostic nerve block response, precise lead placement, shorter duration of symptoms, and patient adherence to follow-up programming and rehabilitation (Arulkumar et al., 2024). Together, these factors highlight the importance of patient selection and individualized planning.
In conclusion, the growing body of evidence supports PNS as an effective, safe, and adaptable therapy for chronic shoulder pain. It offers significant benefits across diverse shoulder pathologies and aligns with modern pain management principles emphasizing minimally invasive, reversible, and targeted interventions. Further large-scale randomized trials will help refine its optimal indications and strengthen its role in clinical practice.
References
Abarca, N., Adams, L., & Rahimi Darabad, R. (2024). The effects of peripheral nerve stimulation on chronic shoulder pain. Neuromodulation.
Arulkumar, S., Neuchat, E. E., Ly, E., Ly, A. I., Fahimipour, K., & Desai, M. J. (2024). Peripheral nerve stimulation of the shoulder: A technical primer. Journal of Pain Research, 17, 1725–1733. https://doi.org/10.2147/JPR.S446901
Gutierrez, G. J., et al. (2024). A single-center retrospective chart review of percutaneous 60-day PNS treatment for shoulder pain. Neuromodulation.
Kaye, A. D., Ridgell, S., Alpaugh, E. S., Mouhaffel, A., Kaye, A. J., Cornett, E. M., Chami, A. A., Shah, R., Dixon, B. M., Viswanath, O., Urits, I., Edinoff, A. N., & Urman, R. D. (2021). Peripheral nerve stimulation: A review of techniques and clinical efficacy. Pain and Therapy, 10(2), 961–972. https://doi.org/10.1007/s40122-021-00298-1
Mazzola, A., & Spinner, D. (2020). Ultrasound-guided peripheral nerve stimulation for shoulder pain: Anatomic review and assessment of the current clinical evidence. Pain Physician, 23, E461–E474.
Shah, A., Malecki, A., Kassa, B., & Rustom, D. (2023). Ultrasound-guided peripheral nerve stimulation for shoulder pain: Suprascapular versus axillary nerve. Neuromodulation.
Valimahomed, A., et al. (2024). Durable multi-dimensional improvement after 60-day PNS for shoulder pain: Real-world evidence. Neuromodulation. (PIIS109471592400309X.pdf)